BerGenBio

BerGenBio to Participate in Carnegie Nordic Healthcare Seminar

BERGEN, Norway, March 4, 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical needs, announced today that the Company will present at

Carnegie's 27th Annual Nordic Healthcare Seminar to be held on March 5th - 6th,

2024 in Stockholm, Sweden.

The presentation will be live streamed by Carnegie on March 6th from 9:40 am

CET. The presentation will also be made available on the Company website in the

Investor/presentations section following the presentation.

www.bergenbio.com/investors/presentations/

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

Media Relations

Jan Lilleby

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate, bemcentinib, a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

AI Terminal